DNA aptamers that bind to MUC1 tumour marker: Design and characterization of MUC1-binding single-stranded DNA aptamers

被引:331
作者
Ferreira, C. S. M.
Matthews, C. S.
Missailidis, S.
机构
[1] Open Univ, Dept Chem, Milton Keynes MK7 6AA, Bucks, England
[2] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England
关键词
aptamers; enzyme-linked immunosorbent assay; fluorescent microscopy; MUC1; surface plasmon resonance; tumour targeting;
D O I
10.1159/000096085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Agents able to bind tightly and selectively to disease markers can greatly benefit disease diagnosis and therapy. Aptamers are functional molecules, usually DNA or RNA oligonucleotides, with the appropriate sequence and structure to form a complex with a target molecule. MUC1 is a well-known tumour marker present in a variety of malignant tumours and it has been a target of interest for many years. In this work we report the selection of DNA aptamers that bind with high affinity and selectivity to the MUC1 peptides. Combinatorial chemistry techniques based on the SELEX methodology were used for the identification of the specific aptamers. These were selected from an initial library containing a 25-base-long variable region, resulting in 4 25 random sequences of single-stranded DNA molecules, for their ability to bind to synthetic forms of MUC1. Ten rounds of in vitro selection were performed enriching for MUC1 binding. By round ten more than 90% of the pool of sequences consisted of MUC1-binding molecules. Selected aptamer families were cloned, sequenced and found to be unique, sharing no sequence consensus. The binding properties of these aptamers were quantitated by enzyme-linked immunosorbent assay and surface plasmon resonance, whereas their specificity for MUC1-expressing cancer cells has been validated using fluorescent microscopy. Aptamers offer significant advantages over existing antibody-based recognition procedures in that they offer higher binding affinity (higher retention/reduced dissociation) and specificity to the target (ability to determine variations on the protein target down to single amino acid changes), higher selectivity against mutated protein epitopes and potentially reduced immunogenicity and increased tumour penetration associated with their size. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:289 / 301
页数:13
相关论文
共 53 条
[1]   Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity [J].
Akhtar, S ;
Dunnion, D ;
Poyner, D ;
Bibby, M ;
Double, J .
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (12) :2187-2195
[2]   Mimics and cross reactions of relevance to tumour immunotherapy [J].
Apostolopoulos, V ;
Sandrin, MS ;
McKenzie, IFC .
VACCINE, 1999, 18 (3-4) :268-275
[3]   Nucleic acid selection as a tool for drug discovery [J].
Bacher, JM ;
Ellington, AD .
DRUG DISCOVERY TODAY, 1998, 3 (06) :265-273
[4]  
Bell C, 1999, IN VITRO CELL DEV-AN, V35, P533
[5]   Specific oligobodies against ERK-2 that recognize both the native and the denatured state of the protein [J].
Bianchini, M ;
Radrizzani, M ;
Brocardo, MG ;
Reyes, GB ;
Solveyra, CG ;
Santa-Coloma, TA .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 252 (1-2) :191-197
[6]   Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels - Selective targeting of endothelial regulatory protein pigpen [J].
Blank, M ;
Weinschenk, T ;
Priemer, M ;
Schluesener, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16464-16468
[7]   SELECTION OF SINGLE-STRANDED-DNA MOLECULES THAT BIND AND INHIBIT HUMAN THROMBIN [J].
BOCK, LC ;
GRIFFIN, LC ;
LATHAM, JA ;
VERMAAS, EH ;
TOOLE, JJ .
NATURE, 1992, 355 (6360) :564-566
[8]  
Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5
[9]   Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat [J].
Brokx, RD ;
Revers, L ;
Zhang, QH ;
Yang, SX ;
Mal, TK ;
Ikura, M ;
Gariépy, J .
BIOCHEMISTRY, 2003, 42 (47) :13817-13825
[10]   DETECTION OF THE TUMOR-ASSOCIATED ANTIGENS RECOGNIZED BY THE MONOCLONAL-ANTIBODIES HMFG-1 AND HMFG-2 IN SERUM FROM PATIENTS WITH BREAST-CANCER [J].
BURCHELL, J ;
WANG, D ;
TAYLORPAPADIMITRIOU, J .
INTERNATIONAL JOURNAL OF CANCER, 1984, 34 (06) :763-768